Promising Type 1 Diabetes Treatment Advances with FDA Pre-IND Meeting

Medical researchers from Kadimastem and iTolerance have achieved a critical milestone in developing a potential cure for Type 1 Diabetes after completing a productive pre-IND meeting with the U.S. Food and Drug Administration. The collaborative research initiative, known as iTOL-102, represents a novel approach to treating diabetes that could revolutionize patient care by eliminating the need for chronic immune system suppression.

The investigational biologic combines Kadimastem's allogenic human stem cell-derived pancreatic islets (IsletRx cells) with iTolerance's immunomodulator technology. During preclinical testing at the Diabetes Research Institute, the treatment demonstrated functional insulin release and disease reversal in animal models, suggesting significant therapeutic potential.

Key to the breakthrough is iTOL-100, an immunomodulatory microgel technology designed to reduce or eliminate systemic immunosuppression following cell transplantation. The technology has shown compatibility with Kadimastem's IsletRx cells, which are capable of detecting glucose levels and producing necessary insulin and glucagon.

The FDA's preliminary feedback provides critical guidance for the next development stages, including plans for a safety toxicology study and preparation for a first-in-human clinical trial. This regulatory interaction represents a crucial step toward potentially transforming diabetes treatment by offering a more sustainable therapeutic approach.

Kadimastem's IsletRx technology offers a scalable and virtually unlimited source of insulin-producing cells, addressing the critical shortage of donor islets for transplantation. The innovative therapy could provide hope for millions of individuals living with Type 1 Diabetes by offering a potential long-term solution that differs significantly from current management strategies.

The collaboration between Kadimastem and iTolerance, supported in part by grants from the Israel-U.S. Binational Industrial Research and Development Foundation, demonstrates the potential of combining advanced stem cell research with innovative immunomodulation techniques to address complex medical challenges.

As the research progresses, the potential impact on diabetes treatment remains substantial. The novel approach could fundamentally change how Type 1 Diabetes is managed, offering patients a more comprehensive and potentially curative treatment option that reduces the long-term medical complications associated with chronic immunosuppression.